Commense Bio
Commense Bio is a biopharmaceutical company focusing on developing genetically engineered bacterial therapeutics for invasive infections. With a proprietary technology platform, the company is advancing live biotherapeutic products (LBPs) addressing various infectious diseases including MRSA, recurrent UTIs, cystic fibrosis-associated infections, and more. Their innovations center around gene-edited bacteria and microbiome substitution—with a single, prescription-only application administered dermally or nasally—as a novel, non-antibiotic approach against antimicrobial resistance. The team includes experience in drug development, commercialization, and scientific research.
Industries
N/A
Patents
Products
Therapeutic candidates targeting MRSA/MSSA (S. aureus), recurrent UTIs (E. coli), cystic fibrosis (P. aeruginosa), surgical infections (S. epidermidis), and acne (C. acnes), utilizing gene-edited bacterial strains for microbiome-based infection control.
Therapeutic candidates targeting MRSA/MSSA (S. aureus), recurrent UTIs (E. coli), cystic fibrosis (P. aeruginosa), surgical infections (S. epidermidis), and acne (C. acnes), utilizing gene-edited bacterial strains for microbiome-based infection control.
Expertise Areas
- Bacterial therapeutic development
- Microbiome engineering
- Live biotherapeutic product research
- Infectious disease therapeutics
Key Technologies
- Genetically engineered bacteria
- Live biotherapeutic products
- Microbiome modulation
- Gene editing platforms
Key People
News & Updates
Announcement related to technology developments and pipeline progress.
Announcement related to technology developments and pipeline progress.